An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics of VIP943 monotherapy in patients with advanced CD123+hematologic malignancies.

被引：0

作者：

Strickland, Stephen Anthony

Curran, Emily K.

Jamy, Omer Hassan

Percival, Mary-Elizabeth

Johnson, Amy J.

Birkett, Joseph

Huang, Xin

Frigault, Melanie M.

Lerchen, Hans-Georg

Stelte-Ludwig, Beatrix

Navarro, Tasheda

Peck, Jim

Gross, Wyatt

Izumi, Raquel

Hamdy, Ahmed M.

Daver, Naval Guastad

机构：

[1] SCRI, TriStar Centennial, Nashville, TN USA

[2] Univ Cincinnati, Cincinnati, OH USA

[3] Univ Alabama Birmingham, Birmingham, AL USA

[4] Fred Hutchinson Canc Ctr, Seattle, WA USA

[5] Vincerx Pharma, Palo Alto, CA USA

[6] Vincerx Pharma, Monheim, Germany

[7] Univ Texas MD Anderson Canc Inst, Houston, TX USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS3167

引用

页数：1